ClinicalTrials.gg
CompletedNCT04669808Updated Sep 24, 2026Results posted

Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With Basal Cell Carcinoma

A Phase 2 interventional study of STP705 in Basal Cell Carcinoma, sponsored by Sirnaomics. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-24.

Sponsored by Sirnaomics · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
32
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 171 studies in Carcinoma, Basal Cell with a site in United States — 23 open to participants now, 38 under way, 2 of them phase 3. Carcinoma, Basal Cell · United States.

Enrollment
80th of 139
32 · median 40
Started
2020
with 7 others
Phase 2
46 of 171
6 open now
Registered
122nd of 171
by date

Among the 171 studies in Carcinoma, Basal Cell with a site in United States, this one is the 80th largest by enrollment of the 139 interventional ones that give a count, is one of 8 that started in 2020, is one of 46 in phase 2, and was the 122nd registered.

Carcinoma, Basal Cell

389 studies on the registry are indexed under Carcinoma, Basal Cell; 69 are open to participants now.

Browse Carcinoma, Basal Cell studies →

Open to participants now

23 of the 171 studies in Carcinoma, Basal Cell with a site in United States are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 52 Carcinoma, Basal Cell studies recruiting now, 48 (92%) set no upper age limit and none (0%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 171 studies in Carcinoma, Basal Cell with a site in United States, or all of them as a file.
02

Study summary

This phase 2, open label, dose escalation study is designed to evaluate the safety, tolerability and efficacy of various doses of STP705 administered as localized injection in patients with Basal Cell Carcinoma (BCC).

Goals:

  • To determine the safe and effective recommended dose of STP705 for the treatment of basal cell carcinoma.
  • Analysis of biomarkers common to BCC formation pathway including TGF-β1 and COX-2.
Read the detailed description

Basal cell carcinoma occurs most often on areas of the skin that are exposed to the sun, such as head and neck. The most commonly found clinical feature of Basal Cell Carcinoma (BCC) is an elevated tumor with a pearly and translucent margin and telangiectasia. The color may vary widely from nearly normal skin color to erythematous to violaceous and may also be pigmented. BCC may also resemble noncancerous skin conditions such as eczema or psoriasis. The majority of these cancers occur on areas of skin that are regularly exposed to sunlight or other ultraviolet radiation.

The STP705 drug substance (STP705) is composed of two siRNA oligonucleotides, targeting the expression of TGF-β1 and Cox-2 mRNA respectively. Along with the HKP-enhanced delivery system, the combination is expected to downregulate TGF-β1 and COX-2 expression resulting in the inhibition of tumor growth and provide an alternative non-invasive approach for the treatment of BCC.

This phase 2, open label, dose escalation study is designed to evaluate the safety, tolerability and efficacy of various doses of STP705 administered as localized injection in patients with BCC. This study seeks to establish a safe and effective recommended dose of STP705 for the treatment of BCC. The clinician will evaluate the change in tumor size at each treatment visit. At the End of Treatment visit, the residual tumor, or former tumor location, will be excised for analysis. Expression of biomarkers common to the BCC formation pathway, including TGF-β1 and COX-2, will be evaluated.

Safety and tolerability will be assessed by the number of incidence of adverse events (AEs) and serious adverse events (SAEs); the incidence of AEs and SAEs leading to discontinuation of trial medication; the incidence and severity of Local Skin Response (LSR); hypopigmentation and hyperpigmentation following treatment; and the tolerability of repeated localized administration of STP705 as assessed by investigator-evaluation of injection site reactions for all patients and within each cohort.

The study plans to enroll approximately 35 adult patients at up to 3 clinical sites in the United States. The 35 patients will be divided equally among 7 cohorts (30, 60, 90, 120, 180, 240, and 320 μg dose level) of 5 patients each.

03

Conditions studied

  • Basal Cell Carcinoma

Browse trials for

Keywords

  • BCC
  • STP705
  • Basal Cell Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: Subjects are required to meet all of the following criteria for enrollment into the study:

  1. Male or female adult ≥ 18 years of age.
  2. Primary, confirmed trunk or extremity (non-peri-orbital/-anogenital/-facial/-scalp) basal cell carcinoma lesion suitable for excision with a minimum diameter of 0.5 cm and with a maximum diameter of 2.0 cm.
  3. Histological diagnosis made no more than 6 months prior to the screening visit.
  4. Histological removed ≤25% of the original volume of the target lesion.
  5. No other dermatological disease in the BCC target site or surrounding area, which in the opinion of the investigator, could interfere with the study.
  6. Willing to refrain from using non-approved lotions or creams on the target site and surrounding area during the treatment period.
  7. Willing to refrain from exposure to excessive direct sunlight or ultraviolet light and to avoid the use of tanning parlors for the duration of the study.
  8. Laboratory values for the tests (listed in the Study Schedule) within the reference ranges as defined by the central laboratory, or "out of range" test results that is clinically acceptable to the investigator. Ability to follow study instructions and likely to complete all study requirements.
  9. Written obtained, including consent for tissue to be examined and stored by the Central Histology Lab.
  10. Written consent to allow photographs of the target BCC lesion to be used as part of the study data and documentation.
  11. For females of , a negative pregnancy test at screening and using an acceptable form of (oral / implant/ injectable/ transdermal contraceptives, intrauterine device, condom, diaphragm, abstinence, or a monogamous relationship with a partner who has had a vasectomy).

Exclusion Criteria:

  1. Pregnant or lactating.
  2. Presence of known or suspected systemic cancer.
  3. Histological evidence of SCC, or any other non-BCC tumor in the biopsy specimen.
  4. Histological evidence of infiltrative or other aggressive histological subtype growth patterns in the biopsy specimen.
  5. History of recurrence of the target BCC lesion.
  6. Evidence of dermatological disease or confounding skin condition with in 2 cm margin of the target BCC lesion, e.g., SCC, actinic keratosis, rosacea, psoriasis, atopic dermatitis, eczema, xeroderma pigmentosa.
  7. Concurrent disease or treatment that suppresses the immune system;
  8. Patients with baseline QTC > 480 msec using Frederica's formula.
  9. Chronic medical condition that in the judgment of the investigator(s) would interfere with the performance of the study or would place the patient at undue risk.
  10. Known sensitivity to any of the ingredients in the study medication.
  11. Use of a tanning beds or other excessive or prolonged exposure to ultraviolet light or direct sunlight during the study.
  12. Treatment with systemic chemotherapeutic agents within the 6 months prior to the screening visit.
  13. Use of systemic retinoids within the 6 months prior to the screening period.
  14. Treatment with systemic immunomodulators or within the 6 months prior to the screening period.
  15. Use of topical immunomodulators within 2 cm of the target BCC lesion within the 4 weeks prior to the screening period.
  16. Treatment with the following topical agents within 2 cm of the target BCC lesion within the 4 weeks prior to the screening visit: amino-levulinic acid, 5-fluorouracil, , retinoids, diclofenac, ingenol mebutate, or imiquimod.
  17. Treatment with liquid nitrogen, surgical excision (excluding diagnostic incisional biopsy) or curettage within 2 cm of the target BCC lesion during the 4 weeks prior to the screening visit.
  18. Evidence of current chronic alcohol or drug abuse.
  19. Current enrollment in an drug or device study or participation in such a study within 4 weeks of the screening visit.
  20. In the investigator's opinion, evidence of unwillingness, or inability to follow the restrictions and requirements of the protocol and complete the study.
  21. Taking any other investigational product within 1 month of first dose of STP705.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Cohort A: STP705 30 μg dose

    Cohort A: STP705 30 μg dose, localized injection, given once a week for 6 weeks

    Drug: STP705

  • Experimental
    Cohort B: STP705 60 μg dose

    Cohort B: STP705 60 μg dose, localized injection, given once a week for 6 weeks

    Drug: STP705

  • Experimental
    Cohort C: STP705 90 μg dose

    Cohort C: STP705 90 μg dose, localized injection, given once a week for 6 weeks

    Drug: STP705

  • Experimental
    Cohort D: STP705 120 μg dose

    Cohort D: STP705 120 μg dose, localized injection, given once a week for 6 weeks

    Drug: STP705

  • Experimental
    Cohort E: STP705 180 μg dose

    Cohort E: STP705 180 μg dose, localized injection, given once a week for 6 weeks

    Drug: STP705

  • Experimental
    Cohort F: STP705 240 μg dose

    Cohort F: STP705 240 μg dose, localized injection, given once a week for 6 weeks

    Drug: STP705

  • Experimental
    Cohort G: STP705 320 μg dose

    Cohort G: STP705 320 μg dose, localized injection, given once a week for 6 weeks

    Drug: STP705

Interventions

  • DrugSTP705

    Dry powder for intra-and peri-lesional injection.

    Also known as: STP705 Powder for Injection

06

What researchers measure

Primary outcomes

  1. Proportion of Participants With Histological Clearance of Treated Basal Cell Carcinoma Lesion at the End of Treatment (EOT)

    Histological clearance (HC) will be defined as the absence of detectable evidence of BCC tumor cell nests as determined by central pathology review.

    Time frame: 6 weeks

Secondary outcomes

  1. Change in Clinical Diameter of the Treated Basal Cell Carcinoma Lesion Over the 6 Week Treatment Period

    A baseline assessment of lesion clinical diameter will be made by investigator at T1 (first visit). The change in size from baseline to the End of Treatment (EOT) visit (Week 6) will be reported.

    Time frame: End of Treatment (EOT) visit (Week 6)

07

Results

Posted Sep 24, 2026

Participant flow

Participant flow — Overall Study
MilestoneCohort A: STP705 30 μg DoseCohort B: STP705 60 μg DoseCohort C: STP705 90 μg DoseCohort D: STP705 120 μg DoseCohort E: STP705 180 μg DoseCohort F: STP705 240 μg DoseCohort G: STP705 320 μg Dose
Started5566550
Completed5555550
Not completed0011000

Outcome measures

PrimaryProportion of Participants With Histological Clearance of Treated Basal Cell Carcinoma Lesion at the End of Treatment (EOT)

Histological clearance (HC) will be defined as the absence of detectable evidence of BCC tumor cell nests as determined by central pathology review.

Time frame:
6 weeks
Reported as:
Count of participants · Participants
Proportion of Participants With Histological Clearance of Treated Basal Cell Carcinoma Lesion at the End of Treatment (EOT)
ParticipantsCohort A: STP705 30 μg DoseCohort B: STP705 60 μg DoseCohort C: STP705 90 μg DoseCohort D: STP705 120 μg DoseCohort E: STP705 180 μg DoseCohort F: STP705 240 μg Dose
Proportion of Participants With Histological Clearance of Treated Basal Cell Carcinoma Lesion at the End of Treatment (EOT)133253
SecondaryChange in Clinical Diameter of the Treated Basal Cell Carcinoma Lesion Over the 6 Week Treatment Period

A baseline assessment of lesion clinical diameter will be made by investigator at T1 (first visit). The change in size from baseline to the End of Treatment (EOT) visit (Week 6) will be reported.

Time frame:
End of Treatment (EOT) visit (Week 6)
Reported as:
Mean · millimeters (mm)
Change in Clinical Diameter of the Treated Basal Cell Carcinoma Lesion Over the 6 Week Treatment Period
millimeters (mm)Cohort A: STP705 30 μg DoseCohort B: STP705 60 μg DoseCohort C: STP705 90 μg DoseCohort D: STP705 120 μg DoseCohort E: STP705 180 μg DoseCohort F: STP705 240 μg Dose
Change in Clinical Diameter of the Treated Basal Cell Carcinoma Lesion Over the 6 Week Treatment Period0 (0 to 0)0 (0 to 0)0 (0 to 0)0 (0 to 0)0 (0 to 0)-0.6 (-2.0 to 0)

Adverse events

Collected over from enrollment until end of follow-up, up to 10 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort A: STP705 30 μg Dose0/5 (0%)0/5 (0%)1/5 (20%)
Cohort B: STP705 60 μg Dose0/5 (0%)0/5 (0%)3/5 (60%)
Cohort C: STP705 90 μg Dose0/6 (0%)0/6 (0%)3/6 (50%)
Cohort D: STP705 120 μg Dose0/6 (0%)0/6 (0%)4/6 (66.7%)
Cohort E: STP705 180 μg Dose0/5 (0%)0/5 (0%)2/5 (40%)
Cohort F: STP705 240 μg Dose0/5 (0%)0/5 (0%)0/5 (0%)
Cohort G: STP705 320 μg Dose———
Most frequent other events
Showing 10 of 13
Most frequent other events
EventCohort A: STP705 30 μg DoseCohort B: STP705 60 μg DoseCohort C: STP705 90 μg DoseCohort D: STP705 120 μg DoseCohort E: STP705 180 μg DoseCohort F: STP705 240 μg DoseCohort G: STP705 320 μg Dose
ChillsGeneral disorders1/50/50/60/60/50/5—
MyalgiaMusculoskeletal and connective tissue disorders0/51/50/60/60/50/5—
ArthralgiaMusculoskeletal and connective tissue disorders0/51/50/60/60/50/5—
HeadacheNervous system disorders0/51/50/60/60/50/5—
Skin LacerationInjury, poisoning and procedural complications0/50/50/60/61/50/5—
Atrial FibrillationCardiac disorders0/50/50/60/61/50/5—
DizzinessNervous system disorders0/50/51/60/60/50/5—
PyrexiaGeneral disorders0/50/51/60/60/50/5—
Staphylococcal Skin InfectionInfections and infestations0/50/51/60/60/50/5—
Aspartate Aminotransferase IncreasedInvestigations0/50/50/61/60/50/5—

Baseline characteristics

The study was closed by the sponsor prior to Cohort G, STP705 320 μg dosing.

Age, Categorical
Age, Categorical(Participants)Cohort A: STP705 30 μg DoseCohort B: STP705 60 μg DoseCohort C: STP705 90 μg DoseCohort D: STP705 120 μg DoseCohort E: STP705 180 μg DoseCohort F: STP705 240 μg DoseTotal
<=18 years0000000
Between 18 and 65 years24132315
>=65 years31533217
Age, Continuous
Age, Continuous(years)Cohort A: STP705 30 μg DoseCohort B: STP705 60 μg DoseCohort C: STP705 90 μg DoseCohort D: STP705 120 μg DoseCohort E: STP705 180 μg DoseCohort F: STP705 240 μg DoseTotal
Median69 (51 to 76)58 (46 to 75)71 (39 to 95)67.5 (52 to 75)73 (49 to 80)60 (46 to 85)69 (39 to 95)
Sex: Female, Male
Sex: Female, Male(Participants)Cohort A: STP705 30 μg DoseCohort B: STP705 60 μg DoseCohort C: STP705 90 μg DoseCohort D: STP705 120 μg DoseCohort E: STP705 180 μg DoseCohort F: STP705 240 μg DoseTotal
Female14321314
Male41344218
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort A: STP705 30 μg DoseCohort B: STP705 60 μg DoseCohort C: STP705 90 μg DoseCohort D: STP705 120 μg DoseCohort E: STP705 180 μg DoseCohort F: STP705 240 μg DoseTotal
American Indian or Alaska Native0000000
Asian0000000
Native Hawaiian or Other Pacific Islander0000000
Black or African American0000000
White55665532
More than one race0000000
Unknown or Not Reported0000000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort A: STP705 30 μg DoseCohort B: STP705 60 μg DoseCohort C: STP705 90 μg DoseCohort D: STP705 120 μg DoseCohort E: STP705 180 μg DoseCohort F: STP705 240 μg DoseTotal
Hispanic or Latino0001001
Not Hispanic or Latino55655531
Unknown or Not Reported0000000
Region of Enrollment
Region of Enrollment(participants)Cohort A: STP705 30 μg DoseCohort B: STP705 60 μg DoseCohort C: STP705 90 μg DoseCohort D: STP705 120 μg DoseCohort E: STP705 180 μg DoseCohort F: STP705 240 μg DoseTotal
United States55665532
Longest Diameter of Lesion (mm)
Longest Diameter of Lesion (mm)(millimeters (mm))Cohort A: STP705 30 μg DoseCohort B: STP705 60 μg DoseCohort C: STP705 90 μg DoseCohort D: STP705 120 μg DoseCohort E: STP705 180 μg DoseCohort F: STP705 240 μg DoseTotal
Mean11.8 (6.0 to 18.0)11.8 (9.0 to 14.0)11.2 (7.0 to 17.0)10.0 (6.0 to 13.0)10.0 (6.0 to 13.0)10.8 (5.0 to 19.0)10.9 (5.0 to 19.0)
08

Study locations

1 site
  • Center for Clinical and Cosmetic Research
    Aventura, Florida 33180, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2020 to primary completion in Feb 2023, 25 months.

Results were first posted in Sep 2026, 3 years 7 months after primary completion.

Of 43 phase 2 interventional studies under Carcinoma, Basal Cell, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 67. This study's 25 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2020
First posted
Dec 17, 2020
StartActual
Dec 28, 2020
Primary completionActual
Feb 9, 2023
CompletionActual
Feb 9, 2023
Results first posted
Sep 24, 2026
Last update
Sep 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04669808
Lead sponsor
Sirnaomics
Collaborators
Amarex Clinical Research
Responsible party
Sponsor
First posted
Dec 17, 2020
Start date
Dec 28, 2020
Primary completion
Feb 9, 2023
Completion
Feb 9, 2023
Results posted
Sep 24, 2026
Last update
Sep 24, 2026

Study contacts

Mark Nestor, MD, PhD
principal investigator · Center for Clinical and Cosmetic Research

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cotsiranib

Start the discussion